ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$15.30 USD
+0.55 (3.73%)
Updated Jun 21, 2024 04:00 PM ET
After-Market: $15.33 +0.03 (0.20%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Brokerage Reports
ACADIA Pharmaceuticals Inc. [ACAD]
Reports for Purchase
Showing records 121 - 140 ( 243 total )
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 and Clinical Trials: A Combo That Doesn''t Mix?
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Persistent Nuplazid Growth Complemented by Pimavanserin Catalysts Approaching in 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead to 2020 Catalysts With Anticipated Milestones for Pimavanserin Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Pimavanserin Phase 3 HARMONY Trial Topline Meets Primary and Key Secondary Endpoint at CTAD?19
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
ADVANCE Topline Win Adds Momentum to Indication Expansion Endeavour
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Pipeline in a Drug CNS Development Complimented by Trofinetide Pivotal Trial Initiation; Reit Buy and $60 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
HARMONY Interim Hit Supports Pipeline in a Drug Thesis; Reit Buy and $60 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Strength in Underlying Business Frames Important Pipeline Catalysts Ahead
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Our Thoughts Following the Topline Miss of the Phase 3 ENHANCE study
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Viewing the Upcoming Schizophrenia Trials Through the Lens of Literature; Reit Buy and $60 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A